Review: Ipratropium is not more effective than β[sub2]-agonists for acute exacerbartions of chronic obstructive pulmonary disease

McCrory, D.C.; Brown, C.D.; Niewoehner, Dennis E.
May 2003
ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p73
Academic Journal
Summarizes a study that investigated whether anticholinergic agents are more effective than placebo or β[sub2]-agonists in patients with acute exacerbations of chronic obstructive pulmonary disease. Sources of the information used in the study; Main results of the study; Conclusion.


Related Articles

  • Safety of Inhaled Anticholinergics for COPD Scrutinized. Elliott, William T. // Critical Care Alert;Nov2008 Pharmacology Watch, p1 

    The article focuses on the safety of inhaled anticholinergics for the treatment of chronic obstructive pulmonary disease (COPD).

  • Tiotropium and chronic obstructive pulmonary disease. McIvor, R. Andrew // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/13/2010, Vol. 340 Issue 7746, p546 

    The author argues that the inhaled, long acting anticholinergic drug tiotropium is a safe and effective foundation treatment for patients with chronic obstructive pulmonary disease (COPD). The benefits of the drug based on the results of several clinical trials are cited, including improvements...

  • Inhaled anticholinergics for COPD. Tanzi, Maria G. // Pharmacy Today;Dec2008, Vol. 14 Issue 12, p23 

    The article presents a study concerning the effectiveness of the inhaled anticholinergics for chronic obstructive pulmonary disease (COPD) treatment. Research shows that anticholinergics such as ipratropium and tiotropium were associated with increased risk for cardiovascular death in patients...

  • ABC of chronic obstructive pulmonary disease. Currie, Graeme P.; Lipworth, Brian J. // BMJ: British Medical Journal (International Edition);6/17/2006, Vol. 332 Issue 7555, p1439 

    The article presents information on inhaled treatment for patients with chronic obstructive airways disease (COPD). According to the article, all patients with COPD should be prescribed a short acting bronchodilator. The article discusses long acting bronchodilators, inhaled corticosteroids,...

  • Observation on the Curative Effect of Bdesonide/formoterol plus Tiotropium Bromide on Group C and D COPD Patients. LI Hai-feng; LENG Jing; HUANG Wei // Journal of Kunming Medical University / Kunming Yike Daxue Xueba;2014, Vol. 35 Issue 12, p62 

    Objective To evaluate the curative effect of budesonide/formoterol plus tiotropium bromide (tiotropium) on group C and D COPD patients. Methods In this 6-month, randomized, double-blind study, 157 subjects, 50 years of age or older, received budesonide/formoterol plus tiotropium (n = 78) or...

  • Inhaled cortico-steroids and COPD exacerbations.  // Infectious Disease Alert;Apr2010 Primary Care, p8 

    The article discusses research done by R. Agarwal and colleagues on inhaled corticosteroids versus placebo for preventing chronic obstructive pulmonary disease (COPD) exacerbations, published in a 2010 issue of "Chest."

  • Tiotropium better than salmeterol for treating COPD.  // GP: General Practitioner;5/12/2003, p12 

    This article reports that Chronic Obstructive Pulmonary Disease exacerbations and health resource usage are lower among patients treated with tiotropium than those given salmeterol. The tiotropium group suffered 1.07 exacerbations per patient year, compared with 1.23 and 1.49 in the salmeterol...

  • LUNG ALERT: N-Acetylcysteine and disease progression in COPD. Sotkunam, K. // Thorax;Aug2005, Vol. 60 Issue 8, p622 

    This article presents results of a clinical study in which the antioxidant N-acetylcysteine was used to assess whether this drug could reduce the rate of lung function decline, reduce the yearly exacerbation rate, or improve clinical outcomes of chronic obstructive pulmonary disease (COPD). 523...

  • The "Towards a Revolution in COPD Health" study. D'Urzo, Anthony D. // Canadian Family Physician;May2008, Vol. 54, p740 

    The article considers whether salmeterol and fluticasone propionate combination reduces all-cause mortality compared with placebo in patients with chronic obstructive pulmonary disease. According to the author, treatment with salmeterol and fluticasone propionate combination does not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics